These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1058 related items for PubMed ID: 16609011

  • 1. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.
    Mutat Res; 2006 Jan 31; 603(1):74-82. PubMed ID: 16388976
    [Abstract] [Full Text] [Related]

  • 3. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
    Huang HM, Liu JC.
    J Cell Physiol; 2009 Mar 31; 218(3):568-74. PubMed ID: 19006173
    [Abstract] [Full Text] [Related]

  • 4. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Pytel D, Wysocki T, Majsterek I.
    Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep 31; 144(1):85-92. PubMed ID: 16904383
    [Abstract] [Full Text] [Related]

  • 5. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.
    Cancer Res; 2003 May 01; 63(9):2118-26. PubMed ID: 12727828
    [Abstract] [Full Text] [Related]

  • 6. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 7. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
    Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM.
    Clin Cancer Res; 2003 Apr 01; 9(4):1267-73. PubMed ID: 12684394
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.
    Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB.
    Blood Cells Mol Dis; 1997 Dec 01; 23(3):380-94. PubMed ID: 9446752
    [Abstract] [Full Text] [Related]

  • 9. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity.
    Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR, Amarante-Mendes GP.
    Cell Death Differ; 2003 May 01; 10(5):592-8. PubMed ID: 12728257
    [Abstract] [Full Text] [Related]

  • 10. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
    Yu C, Krystal G, Dent P, Grant S.
    Clin Cancer Res; 2002 Sep 01; 8(9):2976-84. PubMed ID: 12231544
    [Abstract] [Full Text] [Related]

  • 11. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ.
    Clin Cancer Res; 2004 Oct 01; 10(19):6661-8. PubMed ID: 15475456
    [Abstract] [Full Text] [Related]

  • 12. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.
    Oncogene; 2007 Apr 12; 26(17):2445-58. PubMed ID: 17043649
    [Abstract] [Full Text] [Related]

  • 13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 14. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M.
    Cancer; 2004 Apr 01; 100(7):1459-71. PubMed ID: 15042680
    [Abstract] [Full Text] [Related]

  • 15. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
    Molnár L, Losonczy H.
    Orv Hetil; 2002 Oct 20; 143(42):2379-84. PubMed ID: 12440260
    [Abstract] [Full Text] [Related]

  • 16. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, Talpaz M, Arlinghaus RB, Lydon NB, Kantarjian H.
    Clin Cancer Res; 1998 Jul 20; 4(7):1661-72. PubMed ID: 9676840
    [Abstract] [Full Text] [Related]

  • 17. STI571 and morpholine derivative of doxorubicin collaborate in inhibition of K562 cell proliferation by inducing differentiation and mitochondrial pathway of apoptosis.
    Jakubowska J, Wasowska-Lukawska M, Czyz M.
    Eur J Pharmacol; 2008 Oct 31; 596(1-3):41-9. PubMed ID: 18782571
    [Abstract] [Full Text] [Related]

  • 18. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z, Sampath J, Fukuda S, Pelus LM.
    Cancer Res; 2005 Sep 15; 65(18):8224-32. PubMed ID: 16166298
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S.
    Cancer Res; 2002 Jan 01; 62(1):188-99. PubMed ID: 11782377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.